Transplacental transfer of cefuroxime in uncomplicated pregnancies and those complicated by hydrops or changes in amniotic fluid volume

Daphne E Holt, Nicholas M Fisk, John A D Spencer, John de Louvois, Rosalinde Hurley, David Harvey

Abstract
The transplacental transfer of cefuroxime was determined at antenatal fetal blood sampling in a cross sectional study of 78 patients between 15–35 weeks' gestation, 8–138 minutes after a maternal intravenous dose of 750 mg. Mean serum cefuroxime concentration, measured by high performance liquid chromatography, was 7.4 (95% confidence interval (CI) 6.8 to 8.1) mg/l in control fetuses; concentrations in hydropic fetuses were similar (6.2 mg/l, CI 4.7 to 7.7) but in fetuses with oligohydramnios they were significantly lower, (4.9 mg/l, CI 3.6 to 6.2). Antibiotic concentration did not correlate with gestational age and remained unchanged by transfusion of packed red cells. We conclude that (i) fetal serum concentrations of cefuroxime obtained after a maternal dose of 750 mg are only adequate for prophylaxis against organisms with a minimum inhibitory concentration of <4 mg/l and (ii) transplacental passage of cefuroxime is significantly reduced in the presence of oligohydramnios.

(Arch Dis Child 1993;68:54-7)

Infection in utero is implicated as a cause of premature rupture of the membranes and preterm labour.1 With the increase in invasive procedures for fetal diagnosis and treatment, and their attendant risk of infection,2 there is renewed interest in the placental transfer of antibiotics used for prophylaxis or treatment.

Transplacental antibiotic treatment is based on the premise that a sufficient concentration will reach the intrauterine environment to treat or prevent infection; however there are few data to substantiate this. In several previous studies, concentrations of antibiotic were measured in cord blood at delivery after maternal administration of the antibiotic during labour,3,4 but this approach gives no indication of concentrations attained in fetal serum in utero. Little consideration has been given to the effects on transplacental transfer of such parameters as gestational age, hydrops, abnormal amniotic fluid volume, or procedures such as intravascular transfusion.

Cefuroxime has a broad spectrum bactericidal activity against organisms associated with intrauterine infections.5 It is relatively resistant to beta-lactamase degradation, well tolerated, and free from toxicity, making it suitable for use in pregnancy.

We therefore determined the extent to which a prophylactic dose of maternally administered cefuroxime was transferred to the fetus before antenatal fetal blood sampling in uncomplicated pregnancies and in those complicated by hydrops or abnormalities in amniotic fluid volume. Additionally, we determined the effect of gestational age and intravascular transfusion on the placental transfer of cefuroxime.

Patients and methods
Mothers undergoing antenatal fetal blood sampling for clinical diagnosis were recruited in this cross sectional study, approved by the local ethics committee. Informed consent for inclusion was given by 78 patients. The concentration of cefuroxime (Zinacef, Glaxo) was determined in fetal serum after a single maternal intravenous dose of 750 mg before antenatal fetal blood sampling at 15–35 weeks’ gestation. The general dosage for adults recommended by the manufacturer is 750 mg three times a day. In our hospital a single dose of 750 mg is administered before an invasive procedure when prophylaxis is considered necessary. Ninety six blood samples of volume 1 ml were collected from fetuses at the time of blood sampling for diagnostic or therapeutic indications. Fifteen samples were obtained from normal fetuses undergoing blood sampling for prenatal diagnosis of various conditions from which they were subsequently demonstrated to be unaffected (group 1). Thirty eight fetuses with mild Rh alloimmunisation were sampled for packed cell volume determination (median 29%, range 11.48%, group 2). 18 of these underwent intravascular transfusion and a sample after transfusion was obtained. None of the fetuses were hydropic and all had normal amniotic fluid volume on ultrasound. Twenty five fetuses with hydrops or abnormal amniotic fluid volumes were also sampled. Thirteen of these had hydrops and polyhydramnios (deepest vertical pool >8 cm), of which five were associated with alloimmunisation and eight were of non-immune origin (group 3). The other 12 had oligohydramnios (deepest vertical pool <3 cm) associated with obstructive uropathy (n=4), intrauterine growth retardation (n=3), or renal agenesis (n=1) or it was of idiopathic origin: cystic
Transplacental transfer of cefuroxime in uncomplicated pregnancies and those complicated by hydrops or changes in amniotic fluid volume

hygroma (n=2), Down's syndrome (n=1), or a cardiac anomaly (n=1) (group 4).

The blood samples were obtained by trans-abdominal ultrasound guided needling of the umbilical cord at the placental insertion or the intrathoracic vein between eight and 138 minutes after administration of antibiotic to the mother. The time interval between maternal administration and fetal blood sampling was determined by the particular clinical procedure. Bolus intravascular transfusions of packed red cells were carried out at a rate of 5–15 ml/min. The volume transfused varied between 20–200 ml and the donor packed cell volume between 0-65–0-80.

Cefuroxime concentrations were measured by high performance liquid chromatography with a coefficient of variation of less than 4%. Statistical comparisons were performed with paired and unpaired Student’s t tests, while relationships between variables were assessed by Pearson’s correlation coefficient and linear regression analysis. Logarithmic transformations of the data were performed where necessary to normalise distributions. The data are expressed as geometric mean with 95% confidence intervals (CI).

**Results**

After a maternal intravenous dose of 750 mg, cefuroxime was detected in all samples of fetal serum (figs 1 and 2). Serum concentrations were not statistically significantly different in fetuses later assessed as normal (group 1, n=15, 6-6 mg/l, 95% CI 5-7 to 7-5 mg/l) and in Rh fetuses (group 2, n=38, 7-7 mg/l, CI 6-9 to 8-5 mg/l). As none of these fetuses had severe Rh alloimmunisation, for example none had hydrops or polyhydramnios and their packed cell volumes were above the value normally associated with circulatory changes and changes in oxygenation, the two groups were therefore pooled (n=53, 7-4 mg/l, CI 6-8 to 8-1 mg/l) and used as controls for further analysis. In general, fetuses from complicated pregnancies (groups 3 and 4) had lower serum concentrations of cefuroxime than the controls. The mean serum concentration of cefuroxime in those fetuses with polyhydramnios and hydrops (group 3, n=13) was 6-2 mg/l (CI 4-7 to 7-7 mg/l) and in those with oligohydramnios (group 4, n=12) it was 4-9 mg/l (CI 3-6 to 6-2 mg/l). However the differences were only statistically significant between the controls and group 4 (p=0-01). In fetuses with hydrops and polyhydramnios, no difference in serum concentrations of cefuroxime was noted between those associated with Rh disease compared with those of non-immune origin. Similarly, in fetuses with oligohydramnios there was no difference between those associated with renal dysfunction, intrauterine growth retardation, or those of idiopathic origin. Using linear regression analysis after logarithmic transformation of the data in figs 1 and 2, there was no significant correlation between fetal serum cefuroxime concentrations and either the time from maternal administration to sampling or gestational age in any of the groups.

After intravascular transfusion, fetal serum concentrations of cefuroxime rose or remained unchanged in 14/18 fetuses, with no significant difference between mean concentrations before and after transfusion. No correlation could be demonstrated between the change in concentration and the time between the samples before and after transfusion (fig 3), or with gestational age, time after maternal administration, or the volume transfused.

**Discussion**

For antibiotic concentrations to be effective for prevention of infection they should either be equal or be in excess of the minimum inhibitory concentration (MIC) for potential pathogens. Where the fetus may be infected, adequate concentrations should be achieved in the fetal circulation. Organisms implicated...
in fetal infection include those isolated from women with postpartum endometritis\(^9\) (that is, *Staphylococcus epidemidis*, \(\alpha\) and \(\beta\)-haemolytic streptococci, and anaerobic streptococci) and those from women with acute chorioamnionitis\(^8\) (that is, group B streptococcus and *Escherichia coli*). In a study of 67 patients with intra-amniotic infection,\(^9\) group B streptococci were isolated from 25% of cases, along with *E coli* (21%), \(\alpha\)-streptococci (15%), and *Klebsiella pneumoniae* (4%). In addition *Staphylococcus aureus* and \(\beta\)-haemolytic streptococci have been implicated in fetal infections after cordocentesis and intravascular transfusion.\(^1,11\)\(^12\) The MIC of cefuroxime for those organisms is generally <1 mg/l. However 20% of *E coli* strains, one of the commonest causes of neonatal sepsis, have MICs between 4 and 16 mg/l,\(^13\) and only 50% of klebsiella strains have an MIC <31 mg/l.\(^14\) While our study demonstrates that cefuroxime crosses the placenta during the second and third trimester to reach concentrations in fetal serum which exceed the MIC for some organisms associated with intrauterine infection, only five fetuses attained serum concentrations of cefuroxime >12 mg/l. It is therefore likely that higher maternal doses would be required to achieve adequate fetal concentrations against *E coli* or klebsiella.

In the presence of hydrops with polyhydramnios there was no reduction in the placental transfer of cefuroxime. In contrast, in oligohydramnios, fetal serum concentrations of the antibiotic were significantly reduced. This decrease in cefuroxime transfer may reflect reduced placental function in pregnancies complicated by this condition and suggests that these fetuses may not be adequately protected by a single maternal dose of 750 mg. This could be particularly important in cases of oligohydramnios where amniocentesis, with its attendant risk of introducing infection, is used for diagnosis and treatment.\(^15\)

The reason for reduced antibiotic transfer in the presence of oligohydramnios remains obscure. Impairment of uteroplacental perfusion in gross polyhydramnios has been suggested,\(^16\) and may imply a reduction in placental transfer. A reduction in uteroplacental perfusion has also been described in growth retardation,\(^17\) and therefore a decrease in placental transfer of cefuroxime might be related to reduced blood flow to the placenta. The cause of the abnormality in amniotic fluid volume did not appear to influence placental transfer, although small numbers precluded statistical comparisons between subgroups.

Generally, antibiotics cross the placenta by simple diffusion with the passage dependent upon the ionisation, liquid solubility, protein binding, and molecular weight of the drug.\(^18\) Protein binding, along with changes in total body water and extracellular water, will also affect distribution in fetal compartments. Cefuroxime was detectable over the entire range of sampling times at virtually constant concentration. Although the time span studied was limited, this may be indicative of a degree of fetal accumulation, as during that time the maternal serum concentrations of the antibiotic decreased exponentially from around 60 mg/l to 10 mg/l (DE Holt *et al*, unpublished data) in accordance with its known pharmacological properties.\(^3\) In adults cefuroxime is excreted almost entirely by the kidneys. Although the fetal kidney is partly functional by the 12th week of gestation, glomerular filtration rate and tubular function continue to mature well into the third trimester.\(^19\) The serum half life of cefuroxime is prolonged from 1.5 hours to approximately 20 hours in adult anuric patients.\(^20\) Thus the apparent accumulation of cefuroxime in the fetus could be due, in part, to reduced renal excretion. Apparent fetal accumulation has been suggested for the first generation cephalosporin cefazolin.\(^21\) Also, with the third generation cephalosporin cefotaxime, fetal concentrations are continuously higher than maternal concentrations when a pharmacokinetic steady state is reached.\(^22\)

We were unable to demonstrate a significant relationship between the transplacental passage of cefuroxime and gestational age. Likewise, intravascular transfusion of packed red cells had no effect on fetal serum concentrations of cefuroxime. In these cases equilibrium occurs very quickly, presumably from fetal tissues or the maternal circulation. Most of the volume of fluid transfused during the procedure is rapidly cleared across the placenta, therefore the fetal intravascular volume is likely to remain unchanged.\(^23\) In neonatal toxicity caused by chloramphenicol, transfusion has only a minimal effect on the serum concentration of the antibiotic.\(^24\) Multiple exchange transfusions or charcoal haemoperfusion are necessary to reduce antibiotic concentrations.\(^25\)

We have demonstrated that cefuroxime crosses the placenta, unaffected by gestational age or packed red cell transfusion, to achieve a serum concentration in the fetus that is effective against organisms with MICs of <4 mg/l. Our observation that only around 5% of fetuses

![Figure 3](http://adc.bmj.com/)

*Figure 3* Change in fetal serum cefuroxime concentrations during intravenous transfusion for Rh alloimmunisation as a function of procedure duration.
Transplacental transfer of cefuroxime in uncomplicated pregnancies and those complicated by hydrops or changes in amniotic fluid volume

attained concentrations >12 mg/l that would be reliably effective against organisms with MICs of 4 mg/l or more, however, suggests that for prophylaxis against some strains of common organisms an increase in dose would be necessary. Fetal serum concentrations of cefuroxime in oligohydramnios are significantly reduced, therefore in these cases a change in regimen might be considered. Further studies are in progress to determine the fetal uptake of an increased dose of cefuroxime.

Dr Fisk was supported by a Joseph Foreman Fellowship from the Royal Prince Alfred Hospital, Sydney, Australia.

The Kartin Centre was in receipt of a grant from the Menninger Trust, Stroud, Gloucester.

Transplacental transfer of cefuroxime in uncomplicated pregnancies and those complicated by hydrops or changes in amniotic fluid volume.

D E Holt, N M Fisk, J A Spencer, J de Louvois, R Hurley and D Harvey

*Arch Dis Child* 1993 68: 54-57
doi: 10.1136/adc.68.1_Spec_No.54

Updated information and services can be found at:
http://adc.bmj.com/content/68/1_Spec_No/54

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/